Prevention
Detection
Diagnosis and Treatment
BGI Real Solution Joint-Laboratory
Covers immunotherapy, targeted therapy, chemotherapy, and genetic variations associated with hereditary cancers
The test offers comprehensive information about the efficacy of immunotherapy by detecting TMB, MSI, HLA and 23 genes related to the efficacy of immunotherapy
A regularly updated built-in database of cancer genome big data ensures exhaustive interpretation, making the test more effective
Multiple detections and quality controls guarantee the final results
Immune checkpoint inhibitors kill cancer cells by blocking immunosuppressive signals and activating T-cells, and can be used to treat a variety of advanced solid cancers.
Common targets of immune checkpoint inhibitors include PD-1, PD-L1, and CTLA-4.
This novel personalized immunotherapy based on cancer neoantigens, enables the development of personalized anti-cancer vaccine injections that promote the immune system of patients to effectively recognize, kill cancer cells and prevent cancer recurrence.
Adoptive cell transfer therapy is an immunotherapy that modifies the patient' s own immune cells to fight cancer cells.
Adoptive cell transfer therapy mainly includes TIL, DC, TCR-T and CAR-T.
BGI´s Oncology Whole Exome Sequencing Test
BGI´s Oncology Whole Exome Sequencing Test-NEO
• Obtaining comprehensive information on the use of targeted, immunological, and chemotherapy drugs, and a genetic risk assessment for patients whose cancer tissue can be obtained
• Obtaining information for patients who wish to enroll in clinical trials of personalized cancer vaccines and cellular therapies, among others.
• WES requirements: fresh cancer tissue/paraffin block/FFPE sections + control peripheral blood PD-L1 IHC
• PD-L1 IHC requirements: fresh tissue, FFPE